Hartwell E A
Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, Houston, USA.
Am J Clin Pathol. 1998 Sep;110(3):281-92. doi: 10.1093/ajcp/110.3.281.
The use of Rh immune globulin (RhIG) has dramatically decreased the incidence of hemolytic disease of the fetus and newborn resulting from the production of anti-D by an Rh-negative woman. However, despite the widespread use of RhIG, instances of Rh immunization continue to occur, most likely through failure to administer RhIG when indicated or in the appropriate dose. This utilization gap can be closed only through continued active surveillance by health care providers. The following report summarizes recommendations for the administration of RhIG, the dose required in various circumstances, prenatal and postnatal serologic testing of the obstetric patient, and the methods used to determine the degree of fetomaternal hemorrhage or the amount of Rh-positive RBCs in the circulation.
Rh免疫球蛋白（RhIG）的使用已显著降低了Rh阴性女性产生抗-D导致的胎儿及新生儿溶血病的发病率。然而，尽管RhIG已广泛使用，但Rh免疫的情况仍持续发生，很可能是由于在需要时未给予RhIG或剂量不当。只有通过医疗保健提供者持续的主动监测，才能填补这一使用差距。以下报告总结了RhIG给药的建议、各种情况下所需的剂量、产科患者的产前和产后血清学检测，以及用于确定胎儿-母体出血量或循环中Rh阳性红细胞数量的方法。
